These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

543 related items for PubMed ID: 22743277

  • 21. Immunotherapies in neurologic disorders.
    Graves D, Vernino S.
    Med Clin North Am; 2012 May; 96(3):497-523, x. PubMed ID: 22703853
    [Abstract] [Full Text] [Related]

  • 22. Multiple sclerosis: closing in on an oral treatment.
    Martin R.
    Nature; 2010 Mar 18; 464(7287):360-2. PubMed ID: 20237554
    [No Abstract] [Full Text] [Related]

  • 23. New management algorithms in multiple sclerosis.
    Sorensen PS.
    Curr Opin Neurol; 2014 Jun 18; 27(3):246-59. PubMed ID: 24759080
    [Abstract] [Full Text] [Related]

  • 24. Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis.
    Iaffaldano P, Lucisano G, Pozzilli C, Brescia Morra V, Ghezzi A, Millefiorini E, Patti F, Lugaresi A, Zimatore GB, Marrosu MG, Amato MP, Bertolotto A, Bergamaschi R, Granella F, Coniglio G, Tedeschi G, Sola P, Lus G, Ferrò MT, Iuliano G, Corea F, Protti A, Cavalla P, Guareschi A, Rodegher M, Paolicelli D, Tortorella C, Lepore V, Prosperini L, Saccà F, Baroncini D, Comi G, Trojano M, Italian iMed-Web database.
    Brain; 2015 Nov 18; 138(Pt 11):3275-86. PubMed ID: 26362907
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
    He A, Spelman T, Jokubaitis V, Havrdova E, Horakova D, Trojano M, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Girard M, Pucci E, Iuliano G, Alroughani R, Oreja-Guevara C, Fernandez-Bolaños R, Grand'Maison F, Sola P, Spitaleri D, Granella F, Terzi M, Lechner-Scott J, Van Pesch V, Hupperts R, Sánchez-Menoyo JL, Hodgkinson S, Rozsa C, Verheul F, Butzkueven H, Kalincik T, MSBase Study Group.
    JAMA Neurol; 2015 Apr 18; 72(4):405-13. PubMed ID: 25665031
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor).
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011 Apr 18; 111(2 Pt 2):93-8. PubMed ID: 21916163
    [No Abstract] [Full Text] [Related]

  • 29. Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis.
    Del Santo F, Maratea D, Fadda V, Trippoli S, Messori A.
    Eur J Clin Pharmacol; 2012 Apr 18; 68(4):441-8. PubMed ID: 22057838
    [Abstract] [Full Text] [Related]

  • 30. Multiple sclerosis: Switching sides--fingolimod versus injectable MS therapies.
    Rossman IT, Cohen JA.
    Nat Rev Neurol; 2015 Jun 18; 11(6):316-7. PubMed ID: 25896088
    [No Abstract] [Full Text] [Related]

  • 31. Multiple sclerosis disease-modifying therapy and pregnancy.
    Miller AE.
    Mult Scler; 2016 May 18; 22(6):715-6. PubMed ID: 27207870
    [No Abstract] [Full Text] [Related]

  • 32. Fingolimod: cardiovascular deaths.
    Prescrire Int; 2012 Apr 18; 21(126):99. PubMed ID: 22515137
    [No Abstract] [Full Text] [Related]

  • 33. A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis.
    Lu E, Wang BW, Alwan S, Synnes A, Dahlgren L, Sadovnick AD, Tremlett H.
    CNS Drugs; 2014 Feb 18; 28(2):89-94. PubMed ID: 24343726
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Trial watch: Phase III promise for oral multiple sclerosis therapy.
    Nat Rev Drug Discov; 2009 Feb 18; 8(2):98. PubMed ID: 19180099
    [No Abstract] [Full Text] [Related]

  • 38. Kaposi sarcoma in a patient with relapsing-remitting multiple sclerosis receiving fingolimod.
    Tully T, Barkley A, Silber E.
    Neurology; 2015 May 12; 84(19):1999-2001. PubMed ID: 25878178
    [No Abstract] [Full Text] [Related]

  • 39. Drugs: An injection of hope.
    Graham-Rowe D.
    Nature; 2012 Apr 12; 484(7393):S4. PubMed ID: 22509505
    [No Abstract] [Full Text] [Related]

  • 40. Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.
    Fazekas F, Berger T, Fabjan TH, Ledinek AH, Jakab G, Komoly S, Kraus J, Kurča E, Kyriakides T, Lisý L, Milanov I, Panayiotou P, Jazbec SS, Taláb R, Traykov L, Turčáni P, Vass K, Vella N, Havrdová E.
    Wien Med Wochenschr; 2012 Aug 12; 162(15-16):354-66. PubMed ID: 22895849
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.